Abstract
Mucopolysaccharidosis I (MPS I) is a genetic disorder caused by mutations on α-L-iduronidase (IDUA) gene, leading to low or null enzyme activity. As nonsense mutations are present in about two thirds of the patients, stop codon read through (SCRT) is a potential alternative to achieve enhanced enzyme activity. This mechanism suppresses premature stop codon mutations allowing the protein to be fully translated. Chloramphenicol is a peptidyl transferase inhibitor able to induce readthrough and is efficient in cross the blood brain barrier. In this work, fibroblasts from MPS I patients (p.W402X/p.W402X; p.R89W/p.W402X and p.Q70X/c.1739-1g>t) were treated with chloramphenicol, which resulted in 100-fold increase on IDUA activity on compound heterozygous fibroblasts. cDNA sequencing showed that only the alleles without the nonsense mutation were being amplified, even after treatment, leading us to suggest that the nonsense alleles were targeted to nonsense-mediated mRNA decay and that chloramphenicol acts through a mechanism other than SCRT.
Keywords: Alpha-l-iduronidase, Chloramphenicol, Mucopolysaccharidosis I, Nonsense Mediated RNA Decay, premature stop codon mutations, stop codon read through
Current Pharmaceutical Biotechnology
Title:Chloramphenicol Enhances IDUA Activity on Fibroblasts from Mucopolysaccharidosis I Patients
Volume: 14 Issue: 2
Author(s): Fabiana Quoos Mayer, Osvaldo Alfonso Artigalas, Valeska Lizzi Lagranha, Guilherme Baldo, Ida Vanessa Schwartz, Ursula Matte and Roberto Giugliani
Affiliation:
Keywords: Alpha-l-iduronidase, Chloramphenicol, Mucopolysaccharidosis I, Nonsense Mediated RNA Decay, premature stop codon mutations, stop codon read through
Abstract: Mucopolysaccharidosis I (MPS I) is a genetic disorder caused by mutations on α-L-iduronidase (IDUA) gene, leading to low or null enzyme activity. As nonsense mutations are present in about two thirds of the patients, stop codon read through (SCRT) is a potential alternative to achieve enhanced enzyme activity. This mechanism suppresses premature stop codon mutations allowing the protein to be fully translated. Chloramphenicol is a peptidyl transferase inhibitor able to induce readthrough and is efficient in cross the blood brain barrier. In this work, fibroblasts from MPS I patients (p.W402X/p.W402X; p.R89W/p.W402X and p.Q70X/c.1739-1g>t) were treated with chloramphenicol, which resulted in 100-fold increase on IDUA activity on compound heterozygous fibroblasts. cDNA sequencing showed that only the alleles without the nonsense mutation were being amplified, even after treatment, leading us to suggest that the nonsense alleles were targeted to nonsense-mediated mRNA decay and that chloramphenicol acts through a mechanism other than SCRT.
Export Options
About this article
Cite this article as:
Quoos Mayer Fabiana, Alfonso Artigalas Osvaldo, Lizzi Lagranha Valeska, Baldo Guilherme, Vanessa Schwartz Ida, Matte Ursula and Giugliani Roberto, Chloramphenicol Enhances IDUA Activity on Fibroblasts from Mucopolysaccharidosis I Patients, Current Pharmaceutical Biotechnology 2013; 14 (2) . https://dx.doi.org/10.2174/1389201011314020009
DOI https://dx.doi.org/10.2174/1389201011314020009 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methodologies to Assess Brain Drug Delivery in Lead Optimization
Current Topics in Medicinal Chemistry In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Overview of Pediatric Epilepsy
Current Pediatric Reviews Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections:
Recent Patents on Regenerative Medicine Age-Dependent Microglial Activation in Immature Brains After Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Occipital Encephalocele: Cause, Incidence, Neuroimaging and Surgical Management
Current Pediatric Reviews Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Ectopic ATP Synthase in Endothelial Cells: A Novel Cardiovascular Therapeutic Target
Current Pharmaceutical Design Host-Cell Survival and Death During Chlamydia Infection
Current Immunology Reviews (Discontinued) From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide Antibiotic
Anti-Infective Agents in Medicinal Chemistry A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging Microwave Assisted Functionalization of Materials: from the Mesoscale to the Nanoscale
Current Organic Chemistry <i>In silico</i> and <i>in vitro</i> Studies of Imidazolium Ionic Liquids as Effective Antibacterial Agents against Multidrug Resistant <i>Escherichia coli</i> Strains
Current Bioactive Compounds The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments
Mini-Reviews in Medicinal Chemistry Registered and Investigational Drugs for the Treatment of Methicillin-Resistant Staphylococcus aureus Infection
Recent Patents on Anti-Infective Drug Discovery